Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-1775 and carboplatin · 1 trial · 1 indication
Descriptive tables that summarize the number and percentage of patients that experience adverse events as categorized in the NCI CTCAE version 4.0 will be generated for the overall population. Laboratory assessments: screening/day 1, 8, 15 of each cycle, and regular physical examination at the start of each cycle or on indication will be performed and followed until 30 days after the end of study (defined as disease progression or unacceptable toxicity (AEs) or patient withdrawal or patient death) or in case of AEs or Stable disease until time of progression.
Radiological assessment (CT scan or MRI) per RECIST 1.1
| Arm | Type | Description |
|---|---|---|
| MK-1775 and carboplatin | EXPERIMENTAL | MK-1775: oral capsules. Carboplatin: intravenous infusion in 30 minutes |
| Name | Type | Description |
|---|---|---|
| MK-1775 and carboplatin | DRUG | Carboplatin will be administered in a dose resulting in AUC5 (i.v. 30 min) at day 1 of each cycle. Concomittantly with the start of the carboplatin infusion 225 mg of MK-1775 will be administered as an oral capsule, followed by 4 additional doses at 12 hour increments ( = 5 BID doses of MK-1775 in 2.5 days in total). One cycle will last 21 days. |
Inclusion Criteria: * Histological or cytological proof of epithelial ovarian cancer, and proven p53 mutated pathway by PCR/Sequencing. IHC will also be performed. In the additional safety and efficacy cohort also inclusion of NSCLC, SCLC, cervical and endometrial cancer (only ovarian cancer cohort...
MK-1775 and carboplatin is an investigational combination being studied for the treatment of epithelial ovarian cancer. It is specifically being evaluated in patients with p53 mutated refractory and resistant ovarian cancer. The combination is in Phase 2 clinical development and is not yet approved by regulatory authorities.
MK-1775 is a Wee-1 inhibitor, which targets the Wee-1 kinase, a protein involved in cell cycle regulation. The combination with carboplatin is being studied in patients with p53 mutated tumors. The study is biomarker-selected, meaning patients are chosen based on the presence of p53 mutations.
MK-1775 and carboplatin is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The combination is currently in Phase 2 clinical development for epithelial ovarian cancer.
MK-1775 and carboplatin is in Phase 2 clinical development. It is an investigational combination and has not received FDA approval. The Phase 2 study has been completed, and the drug remains under investigation for the treatment of epithelial ovarian cancer.
MK-1775 and carboplatin has one completed clinical trial, identified as NCT01164995. This Phase 2 study, titled 'Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer,' enrolled 24 female participants in the Netherlands.
Yes, MK-1775 is also known as AZD1775. The clinical trial NCT01164995 refers to the drug as both MK-1775 and AZD1775. This is the same Wee-1 inhibitor being studied in combination with carboplatin for epithelial ovarian cancer.